BIOFRONTERA AG/ADR (BFRA) Given $23.73 Average Price Target by Analysts
BIOFRONTERA AG/ADR (NASDAQ:BFRA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus target price of $23.73 for the company and are expecting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also given BIOFRONTERA AG/ADR an industry rank of 95 out of 255 based on the ratings given to its competitors.
Several brokerages recently weighed in on BFRA. Zacks Investment Research cut shares of BIOFRONTERA AG/ADR from a “hold” rating to a “sell” rating in a research report on Monday, June 11th. Benchmark began coverage on shares of BIOFRONTERA AG/ADR in a research report on Thursday, June 21st. They issued a “buy” rating and a $20.00 price target on the stock.
Shares of BIOFRONTERA AG/ADR stock traded up $0.09 on Friday, hitting $14.99. 350 shares of the company traded hands, compared to its average volume of 4,385. The stock has a market cap of $320.56 million and a P/E ratio of -16.66. The company has a debt-to-equity ratio of 0.58, a current ratio of 9.90 and a quick ratio of 9.03. BIOFRONTERA AG/ADR has a 52 week low of $11.25 and a 52 week high of $17.98.
BIOFRONTERA AG/ADR (NASDAQ:BFRA) last released its quarterly earnings data on Wednesday, May 30th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.12). The company had revenue of $5.78 million for the quarter. BIOFRONTERA AG/ADR had a negative net margin of 106.21% and a negative return on equity of 148.20%. equities analysts expect that BIOFRONTERA AG/ADR will post -0.4 EPS for the current year.
BIOFRONTERA AG/ADR Company Profile
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.
Recommended Story: Diversification in Your Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.